Idea Transcript
EU Clinical Trials Register Home & Search
Joining a trial
Contacts
Help
About
Clinical trials The European Union Clinical Trials Register allows you to search for protocol and results information on: interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA); clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development. Learn more about the EU Clinical Trials Register including the source of the information and the legal basis. The EU Clinical Trials Register currently displays 32378 clinical trials with a EudraCT protocol, of which 5210 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
X
Please enter search term...
Search
Examples: Cancer AND drug name. Pneumonia AND sponsor name. How to search [pdf]
Advanced Search: Search tools
< Back to search results Summary EudraCT Number:
2004-001403-35
Sponsor's Protocol Code Number:
DOM2004 REDOX
National Competent Authority:
Spain - AEMPS
Clinical Trial Type:
EEA CTA
Trial Status:
Ongoing
Date on which this record was first entered in the EudraCT database:
2006-01-25
Trial results Index A. PROTOCOL INFORMATION B. SPONSOR INFORMATION C. APPLICANT IDENTIFICATION D. IMP IDENTIFICATION D.8 INFORMATION ON PLACEBO E. GENERAL INFORMATION ON THE TRIAL F. POPULATION OF TRIAL SUBJECTS G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED P. END OF TRIAL A. Protocol Information A.1
Member State Concerned
Spain - AEMPS
A.2
EudraCT number
2004-001403-35
A.3
Full title of the trial
A.3.2
Name or abbreviated title of the trial where available
A.4.1
Sponsor's protocol code number
DOM2004 REDOX
A.7
Trial is part of a Paediatric Investigation Plan
Information not present in EudraCT
A.8
EMA Decision number of Paediatric Investigation Plan
Estudio abierto, multicéntrico y aleatorizado sobre la eficacia y seguridad de la reducción de dosis de estavudina en pacientes en tratamiento antirretroviral que incluye estavudina a dosis estándar con buen control virológico e inmunológico.
REDOX
B. Sponsor Information B.Sponsor: 1 B.1.1
Name of Sponsor
Doctor Pere Domingo
B.1.3.4
Country
Spain
B.3.1 and B.3.2
Status of the sponsor
Non-Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial: B.4.1
Name of organisation providing support
B.4.2
Country
B.5 Contact point designated by the sponsor for further information on the trial B.5.1
Name of organisation
B.5.2
Functional name of contact point
D. IMP Identification D.IMP: 1 D.1.2 and IMP Role D.1.3
Test
D.2
Status of the IMP to be used in the clinical trial
D.2.1
IMP to be used in the trial has a marketing authorisation
Information not present in EudraCT
D.2.1.1.1
Trade name
Zerit
D.2.1.1.2
Name of the Marketing Authorisation holder
BRISTOL MYERS SQUIBB PHARMAEEIG
D.2.1.2
Country which granted the Marketing Authorisation
Spain
D.2.5
The IMP has been designated in this indication as an orphan drug in the Community
No
D.2.5.1
Orphan drug designation number
D.3 Description of the IMP D.3.1
Product name
Zerit
D.3.2
Product code
Zerit
D.3.4
Pharmaceutical form
Capsule, hard
D.3.4.1
Specific paediatric formulation
Information not present in EudraCT
D.3.7
Routes of administration for this IMP
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances) D.3.8
INN - Proposed INN
ESTAVUDINA
D.3.10
Strength
D.3.10.1
Concentration unit
mg milligram(s)
D.3.10.2
Concentration type
equal
D.3.10.3
Concentration number
20
D.3.11 The IMP contains an: D.3.11.1
Active substance of chemical origin
Yes
D.3.11.2
Active substance of biological/ biotechnological origin (other No than Advanced Therapy IMP (ATIMP) The IMP is a:
D.3.11.3
Advanced Therapy IMP (ATIMP)
Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product
No
D.3.11.3.2 Gene therapy medical product
No
D.3.11.3.3 Tissue Engineered Product
Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device)
Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product
Information not present in EudraCT
D.3.11.4
Combination product that includes a device, but does not involve an Advanced Therapy
Information not present in EudraCT
D.3.11.5
Radiopharmaceutical medicinal product
No
D.3.11.6
Immunological medicinal product (such as vaccine, allergen, No immune serum)
D.3.11.7
Plasma derived medicinal product
Information not present in EudraCT
D.3.11.8
Extractive medicinal product
Information not present in EudraCT
D.3.11.9
Recombinant medicinal product
Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms No D.3.11.11 Herbal medicinal product
No
D.3.11.12 Homeopathic medicinal product
No
D.3.11.13 Another type of medicinal product
Information not present in EudraCT
D.IMP: 2 D.1.2 and IMP Role D.1.3
Test
D.2
Status of the IMP to be used in the clinical trial
D.2.1
IMP to be used in the trial has a marketing authorisation
Information not present in EudraCT
D.2.1.1.1
Trade name
Zerit
D.2.1.1.2
Name of the Marketing Authorisation holder
BRISTOL MYERS SQUIBB PHARMAEEIG
D.2.1.2
Country which granted the Marketing Authorisation
Spain
D.2.5
The IMP has been designated in this indication as an orphan drug in the Community
No
D.2.5.1
Orphan drug designation number
D.3 Description of the IMP D.3.1
Product name
Zerit
D.3.2
Product code
Zerit
D.3.4
Pharmaceutical form
Capsule, hard
D.3.4.1
Specific paediatric formulation
Information not present in EudraCT
D.3.7
Routes of administration for this IMP
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances) D.3.8
INN - Proposed INN
ESTAVUDINA
D.3.10
Strength
D.3.10.1
Concentration unit
mg milligram(s)
D.3.10.2
Concentration type
equal
D.3.10.3
Concentration number
30
D.3.11 The IMP contains an: D.3.11.1
Active substance of chemical origin
Yes
D.3.11.2
Active substance of biological/ biotechnological origin (other No than Advanced Therapy IMP (ATIMP) The IMP is a:
D.3.11.3
Advanced Therapy IMP (ATIMP)
Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product
No
D.3.11.3.2 Gene therapy medical product
No
D.3.11.3.3 Tissue Engineered Product
Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device)
Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product
Information not present in EudraCT
D.3.11.4
Combination product that includes a device, but does not involve an Advanced Therapy
Information not present in EudraCT
D.3.11.5
Radiopharmaceutical medicinal product
No
D.3.11.6
Immunological medicinal product (such as vaccine, allergen, No immune serum)
D.3.11.7
Plasma derived medicinal product
Information not present in EudraCT
D.3.11.8
Extractive medicinal product
Information not present in EudraCT
D.3.11.9
Recombinant medicinal product
Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms No D.3.11.11 Herbal medicinal product
No
D.3.11.12 Homeopathic medicinal product
No
D.3.11.13 Another type of medicinal product
Information not present in EudraCT
D.IMP: 3 D.1.2 and IMP Role D.1.3
Test
D.2
Status of the IMP to be used in the clinical trial
D.2.1
IMP to be used in the trial has a marketing authorisation
Information not present in EudraCT
D.2.1.1.1
Trade name
Zerit
D.2.1.1.2
Name of the Marketing Authorisation holder
BRISTOL MYERS SQUIBB PHARMAEEIG
D.2.1.2
Country which granted the Marketing Authorisation
Spain
D.2.5
The IMP has been designated in this indication as an orphan drug in the Community
No
D.2.5.1
Orphan drug designation number
D.3 Description of the IMP D.3.1
Product name
Zerit
D.3.2
Product code
Zerit
D.3.4
Pharmaceutical form
Capsule, hard
D.3.4.1
Specific paediatric formulation
Information not present in EudraCT
D.3.7
Routes of administration for this IMP
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances) D.3.8
INN - Proposed INN
ESTAVUDINA
D.3.10
Strength
D.3.10.1
Concentration unit
mg milligram(s)
D.3.10.2
Concentration type
equal
D.3.10.3
Concentration number
40
D.3.11 The IMP contains an: D.3.11.1
Active substance of chemical origin
Yes
D.3.11.2
Active substance of biological/ biotechnological origin (other No than Advanced Therapy IMP (ATIMP) The IMP is a:
D.3.11.3
Advanced Therapy IMP (ATIMP)
Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product
No
D.3.11.3.2 Gene therapy medical product
No
D.3.11.3.3 Tissue Engineered Product
Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device)
Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product
Information not present in EudraCT
D.3.11.4
Combination product that includes a device, but does not involve an Advanced Therapy
Information not present in EudraCT
D.3.11.5
Radiopharmaceutical medicinal product
No
D.3.11.6
Immunological medicinal product (such as vaccine, allergen, No immune serum)
D.3.11.7
Plasma derived medicinal product
Information not present in EudraCT
D.3.11.8
Extractive medicinal product
Information not present in EudraCT
D.3.11.9
Recombinant medicinal product
Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms No D.3.11.11 Herbal medicinal product
No
D.3.11.12 Homeopathic medicinal product
No
D.3.11.13 Another type of medicinal product
Information not present in EudraCT
D.8 Information on Placebo E. General Information on the Trial E.1 Medical condition or disease under investigation E.1.1
Medical condition(s) being investigated
AIDS
MedDRA Classification E.1.3
Condition being studied is a rare disease
No
E.2 Objective of the trial E.2.1
Main objective of the trial
E.2.2
Secondary objectives of the trial
E.2.3
Trial contains a sub-study
E.3
Principal inclusion criteria
E.4
Principal exclusion criteria
Comparar la proporción de sujetos con rebote virológico por encima de 400 copias/ml hasta las 48 semanas de seguimiento, entre los sujetos que cambian a un régimen con estavudina a dosis reducida y aquellos que continúan su régimen actual (dosis estándar de estavudina).
Valoraciones hasta semana 48 en sujetos con régimen de dosis reducida de d4T frente a los que permanecieron con su régimen actual con dosis estándar: 1)Proporción de pacientes y tiempo hasta rebote virológico para estos con niveles de ARN VIH < 50 cp/ml basal.2)El % pacientes con una carga vírica > 1.000 copias/ml hasta semana 48.3)La frecuencia e intensidad de acontecimientos adversos clínicos y de laboratorio y las retiradas por ellos. 4)La magnitud del cambio del recuento de CD4 en la semana 48 respecto al basal.5)Las variaciones de los lípidos en ayunas respecto a los basales.6)Variacines de los parámetros metabólicos en ayunas .7)Variaciones respecto del basal en los niveles de d4T plasmáticos y de d4T-TP intracelulares 4 semanas tras la reducción de dosis. 8)Variaciones en las medidas antropométricas, cuestionario de morfología corporal y DEXA. 9)La intensidad de los síntomas y la toxicidad percibida por el paciente basalmente y hasta la semana 48. Information not present in EudraCT 1. El sujeto es capaz de leer y entender el consentimiento informado aprobado por el correspondiente CEIC, firmándolo voluntariamente, tras habérsele explicado la naturaleza del estudio y haber podido preguntar todo aquello que estime oportuno. 2. Edad superior a los 18 años. 3. El paciente debe estar de acuerdo en continuar su tratamiento actual para el VIH (recordar que la aleatorización se hará en proporción 1:1). 4. Tratamiento antirretroviral triple que incluya estavudina sin modificaciones durante al menos los 6 meses previos a la inclusión en el estudio. Las pautas deberán consistir en 2 NRTIs + 1 NNRTI ó 2 NRTIs + 1 IP (potenciado o no). 5. Antecedentes de tratamiento con ARV: Se permiten dos fracasos virológicos previos como máximo. Se define el fracaso virológico como una carga viral confirmada (dos resultados consecutivos de dos muestras diferentes) por encima del límite de cuantificación de la prueba empleada. Para este estudio, los cambios de algún fármaco componente de la pauta antirretroviral no motivados por rebote virológico no se computarán como fracasos virológicos. 6. El paciente debe tener dos determinaciones consecutivas de niveles plasmáticos de ARN del VIH-1 por debajo del límite de cuantificación (ARN del VIH-1 < 50 copias/ml o, excepcionalmente, 100 células/l durante los últimos 6 meses (Consultar con Monitor Médico si cifras inferiores a 100 cel). 8. Las mujeres en edad fértil (MEF) deben estar usando un método adecuado de anticoncepción para evitar el embarazo durante todo el estudio, de manera que se reduzca al mínimo el riesgo de embarazo
1. Las MEF que no deseen o sean incapaces de usar un método aceptable para evitar el embarazo durante todo el período del estudio. 2. Mujeres embarazadas o en la lactancia. 3. Mujeres con una prueba de embarazo positiva en la visita de selección o antes de la administración del fármaco en estudio. 4. Antecedentes de uso de terapias antirretrovirales subóptimas (mono o biterapia) de duración > 1 año. 5. Esperanza de vida < 12 meses. 6. Presencia de una infección oportunista relacionada con el VIH recién diagnosticada o cualquier trastorno médico que precise tratamiento agudo en el momento o en los 30 días previos a la selección. 7. Peso inferior a 40kg. 8. Diabetes mellitus conocida no controlada (HbA1c > 9% dentro de los 30 días previos a la visita de selección). 9. Uso de alcohol o sustancias suficiente, en opinión del investigador, para impedir un cumplimiento adecuado con el tratamiento en estudio o para aumentar el riesgo de desarrollar pancreatitis, hepatitis o neuropatía. 10. Hepatitis aguda demostrada o sospechada en los 30 días previos a la entrada en el estudio. Los sujetos con hepatitis crónica son elegibles siempre que sus transaminasas hepáticas (ALT/AST) sean < 5 x límite superior a la normalidad. 11. Pacientes que reciben simultáneamente un IP y un inhibidor de la transcriptasa inversa no nucleósido o bien una pauta con tres análogos de nucleósido. 12. Se excluirá aquellos pacientes que reciban o se prevea que vayan a precisar tratamiento durante el estudio con fármacos con potencial neurotoxicidad, así como tratamiento con inmunomoduladores, agentes mielotóxicos o citotóxicos. 13. Presencia de alguna de las siguientes anomalías de laboratorio: a. Hb ≤ 9 g/dl b. Recuento de neutrófilos ≤ 750/uL c. Cifra de plaquetas ≤ 50.000/mL d. ALT o AST > 5 veces por encima del límite superior de la normalidad e. Creatinina > 1,5 veces por encima del límite superior de la normalidad 14. Fármacos o vacunas experimentales administrados en los 30 días anteriores al inicio del estudio. 15. Cualquier motivo que a juicio del investigador impida que el paciente participe en el estudio. 16. Los prisioneros o los sujetos que sean detenidos por la fuerza (encarcelados involuntariamente) para tratamiento de una enfermedad psiquiátrica o física (p. ej., enfermedad infecciosa) no deben ser reclutado en este estudio.
E.5 End points E.5.1
Primary end point(s)
Proporción de sujetos con rebote virológico, definido como dos niveles de ARN del VIH consecutivos > 400 cp/ml hasta la semana 48.
E.6 and E.7 Scope of the trial E.6
Scope of the trial
E.6.1
Diagnosis
Information not present in EudraCT
E.6.2
Prophylaxis
Information not present in EudraCT
E.6.3
Therapy
Yes
E.6.4
Safety
Yes
E.6.5
Efficacy
Yes
E.6.6
Pharmacokinetic
Yes
E.6.7
Pharmacodynamic
Information not present in EudraCT
E.6.8
Bioequivalence
Yes
E.6.9
Dose response
Information not present in EudraCT
E.6.10
Pharmacogenetic
Information not present in EudraCT
E.6.11
Pharmacogenomic
Information not present in EudraCT
E.6.12
Pharmacoeconomic
Information not present in EudraCT
E.6.13
Others
Information not present in EudraCT
E.7
Trial type and phase
E.7.1
Human pharmacology (Phase I)
Information not present in EudraCT
E.7.1.1
First administration to humans
Information not present in EudraCT
E.7.1.2
Bioequivalence study
Information not present in EudraCT
E.7.1.3
Other
Information not present in EudraCT
E.7.1.3.1 Other trial type description E.7.2
Therapeutic exploratory (Phase II)
Yes
E.7.3
Therapeutic confirmatory (Phase III)
Information not present in EudraCT
E.7.4
Therapeutic use (Phase IV)
Yes
E.8 Design of the trial E.8.1
Controlled
Yes
E.8.1.1
Randomised
Yes
E.8.1.2
Open
Yes
E.8.1.3
Single blind
No
E.8.1.4
Double blind
No
E.8.1.5
Parallel group
Yes
E.8.1.6
Cross over
No
E.8.1.7
Other
No
E.8.2
Comparator of controlled trial
E.8.2.1
Other medicinal product(s)
Yes
E.8.2.2
Placebo
No
E.8.2.3
Other
No
E.8.3
The trial involves single site in the Member State concerned No
E.8.4
The trial involves multiple sites in the Member State concerned
Yes
E.8.5
The trial involves multiple Member States
No
E.8.6 Trial involving sites outside the EEA E.8.6.1
Trial being conducted both within and outside the EEA
No
E.8.6.2
Trial being conducted completely outside of the EEA
Information not present in EudraCT
E.8.7
Trial has a data monitoring committee
Information not present in EudraCT
E.8.8
Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
El final del estudio coincide con la última visita del último sujeto reclutado en el ensayo.
E.8.9 Initial estimate of the duration of the trial E.8.9.1
In the Member State concerned years
1
E.8.9.1
In the Member State concerned months
7
E.8.9.1
In the Member State concerned days
F. Population of Trial Subjects F.1 Age Range F.1.1
Trial has subjects under 18
Information not present in EudraCT
F.1.1.1
In Utero
Information not present in EudraCT
F.1.1.2
Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
F.1.1.3
Newborns (0-27 days)
Information not present in EudraCT
F.1.1.4
Infants and toddlers (28 days-23 months)
Information not present in EudraCT
F.1.1.5
Children (2-11years)
Information not present in EudraCT
F.1.1.6
Adolescents (12-17 years)
Information not present in EudraCT
F.1.2
Adults (18-64 years)
Yes
F.1.3
Elderly (>=65 years)
Information not present in EudraCT
F.2 Gender F.2.1
Female
Yes
F.2.2
Male
Yes
F.3 Group of trial subjects F.3.1
Healthy volunteers
No
F.3.2
Patients
Yes
F.3.3
Specific vulnerable populations
Information not present in EudraCT
F.3.3.1
Women of childbearing potential not using contraception For Yes clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2006-01-25.
F.3.3.2
Women of child-bearing potential using contraception
Information not present in EudraCT
F.3.3.3
Pregnant women
No
F.3.3.4
Nursing women
No
F.3.3.5
Emergency situation
No
F.3.3.6
Subjects incapable of giving consent personally
No
F.3.3.7
Others
No
F.4 Planned number of subjects to be included F.4.1
In the member state
284
F.4.2
For a multinational trial
F.4.2.1
In the EEA
284
F.4.2.2
In the whole clinical trial
284
G. Investigator Networks to be involved in the Trial N. Review by the Competent Authority or Ethics Committee in the country concerned N.
Competent Authority Decision
Authorised
N.
Date of Competent Authority Decision
2005-04-18
N.
Ethics Committee Opinion of the trial application
Favourable
N.
Ethics Committee Opinion: Reason(s) for unfavourable opinion
N.
Date of Ethics Committee Opinion
2005-01-26
P. End of Trial P.
End of Trial Status
Ongoing
EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu European Medicines Agency © 1995-2018 | 30 Churchill Place, Canary Wharf, London E14 5EU